HIV/AIDS remains one of the world’s most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis. The present study, published in PLoS ONE and led by researchers from Hospital Clinic de Barcelona-IDIBAPS, within the framework of HIVACAT, shows for the first time that dendritic cells in HIV-infected patients who spontaneously control the infection produce high levels of α-defensins 1 -3. This is associated with slower disease progression, suggesting potential diagnostic, therapeutic and preventive implications. The first author of this study is Dr. Marta Rodriguez-Garcia, Emili Letang Fellowship award from Hospital Clinic of Barcelona for her work in this line of research, and currently a postdoc at The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard. The senior researchers of the study are Dr. Teresa Gallart, from the Immunology Service of Hospital Clinic and collaborator of the IDIBAPS team on Infectious Diseases and AIDS, and Dr. Josep M ª Gatell, Head of the Infectious Diseases Department at the Hospital Clinic, professor at the Department of Medicine of the University of Barcelona and leader of the same IDIBAPS team.
The Official Medical College of Barcelona, Keiretsu Forum Barcelona and Barcelona Activa organized last November 4, 2009 the 1st Healthcare Investment Forum Barcelona’09, in collaboration with Biocat and other institutions. The objective of this forum was to contact young entrepreneurs in the health sector with projects in biotechnology, medical devices, health services and information technology with venture capital investors interested in this sector.
This first edition of the Forum was a success. Over 35 companies presented their projects, of which 12 were finally selected. Three of the finalists were submitted by Hospital Clinic:
The Carlos III Health Institute, a public body under the Ministry of Science and Innovation, has created two new stable cooperative research structures to boost Biobanks and Innovation in Spanish centers. The Hospital participates in these two initiatives, as well as in most of the already operating CIBERs i RETICS.
The RETICS (Cooperative Thematic Networks in Biomedical Research) have an expected duration of 4 years and consist of professionals from different institutions. They aim to promote complementarity of activities, resource sharing and lines of research, development and innovation. The two new structures established this year are the RETICS of Biobanks and the RETICS of Innovation in Medical and Health Technologies.
Performing surgical operations without leaving scars has ceased to be a chimera and has become a reality. This is demonstrated by the recent surgical advances made using NOTES (Natural Orifice Transluminal Endoscopy Surgery), an innovative surgical approach that allows surgical access using the body’s natural orifices. The results are all advantageous for the patient: lack of scars, shorter hospital stay and faster recovery. Currently, this type of minimally-invasive surgery is still in the research and development stage. Surgery through the mouth and vagina has been successfully used, but the transanal route (through the anus) is less utilized.
A study carried out in the United States has managed to introduce into the muscle cells of macaque monkeys the DNA necessary to produce an antibody-like molecule that is effective against SIV, the virus that causes AIDS in simians. The strategy consists of injecting an adenovirus that introduces the necessary DNA sequence into the nucleus of the muscle cells of the macaques. The researcher, Eloísa Yuste is one of the authors of the study and currently works on the IDIBAPS-Hospital Clínic team led by Dr. Josep Maria Gatell, co-director of HIVACAT(*).
The joint effort of the two institutions has led to some highly notable results over the past decade. Peter Löscher, the chief executive of the German brand at world level, visited the facilities of the Catalan center, which uses advanced technology developed by Siemens, one of the biggest providers in the health care industry. These include the CORE laboratory and all the diagnostic imaging technology, the basis of the Stroke Functional Unit, which has been in operation for six months.
